Abstract:
Objective To investigate the diagnostic value and regulatory function of Cyclin B2 (CCNB2) in lung adenocarcinoma (LUAD).
Methods One hundred specimens from patients with LUAD who were admitted to the Huai'an Hospital between October 2016 and October 2019 were collected to detect the expression of CCNB2 in clinical tissues. The diagnostic value of CCNB2 in LUAD was analyzed using receiver operating characteristic (ROC) curves. The relationship between CCNB2 expression and clinical stage was analyzed based on The Cancer Genome Atlas (TCGA) database. The expression levels of CCNB2 in LUAD and normal cells were detected using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot (WB). Cell cycle proteins were also detected in the cells and cancer tissues using Western blot. The effects of CCNB2 on the proliferation, invasion, and migration of LUAD cells were detected using colony formation, CCK-8, Transwell, and wound healing assays. The cell cycle was analyzed using flow cytometry.
Results CCNB2 expression was significantly higher in LUAD tissues than that in normal tissues. The area under the curve (AUC) was 0.902, indicating that CCNB2 had a good diagnostic value for LUAD. Silencing CCNB2 inhibited the proliferation, invasion, and migration of LUAD cells and blocked the cell cycle in the G0/G1 phase. Silencing CCNB2 inhibit progression of lung adenocarcinoma in mice.
Conclusions CCNB2 can be a diagnostic marker for LUAD, and the downregulation of CCNB2 expression can inhibit the proliferation, invasion, and migration of LUAD cells, indicating its potential as a therapeutic target for LUAD.